In his current role as President and COO at Lykan, he is responsible for driving dynamic growth of the company, developing infrastructure and efficiencies, while ensuring successful execution and delivery to our clients.
Prior to joining Lykan, Patrick spent nineteen years at Pfenex Inc., which began with the spin out of the novel protein production platform from The Dow Chemical Company into a stand-alone biotechnology company. Patrick played an instrumental role in the development of Pfenex’s initial strategy and then evolving that strategy over time to derive greater value from the platform. Pfenex successfully completed an initial public offering in 2014 and received their first FDA product approval in 2019. Patrick and his team built the diverse Pfenex portfolio through licensing, development agreements and partnerships, which ultimately led to the acquisition of the company by Ligand Pharmaceuticals in 2020.
Prior to The Dow Chemical Company and Pfenex Inc. Patrick held various roles in business development, operations, QC, validation and capital project management at Repligen Corporation, Celltech Biologics, Lonza Biologics and Collaborative BioAlliance.
What inspires Patrick is the ability to work with innovative scientific teams to develop cutting edge technologies to address unmet or inadequately met medical need.